Welcome to our dedicated page for TransMedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on TransMedics Group stock.
TransMedics Group, Inc. reports developments in medical technology for organ transplant therapy, centered on its Organ Care System, or OCS, for preserving and monitoring donor lungs, hearts and livers outside the body. Company updates commonly cover OCS utilization through the National OCS Program, transplant logistics services, aviation fleet capacity, revenue trends and margin drivers.
Recurring news also includes clinical and regulatory disclosures tied to OCS programs and the Controlled Hypothermic Organ Preservation System, tax-accounting updates, material agreements, governance actions and employee equity awards. These developments reflect the company's commercial-stage model in organ preservation, transplant logistics and transplant-service support.
TransMedics (Nasdaq: TMDX) said members of its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 3:00 pm PST / 6:00 pm EST. The presentation will be available live and as an archived webcast on the company’s Investors website. The company also noted its standard investor presentation is available at the same link.
TransMedics (Nasdaq: TMDX) announced inducement equity grants dated Dec 22, 2025 for five new employees under Nasdaq Listing Rule 5635(c)(4) and the TransMedics Inducement Plan.
The company granted an aggregate of 6,333 non-qualified stock options and 4,205 restricted stock units (RSUs). The options carry a per-share exercise price of $129.35 (closing price on Dec 22, 2025) and a 10-year term. Option vesting: 25% on first anniversary of start date, remainder monthly over the next three years, subject to continued service. RSU vesting: 25% on each of the first four anniversaries of the start date, subject to continued service. Grants were approved by the Compensation Committee.
TransMedics (NASDAQ:UDMY) announced a strategic collaboration with Mercedes-Benz to deploy a purpose-built Mercedes-Benz V-Class fleet and establish four Italian National OCS Program (NOP) hubs in Milan, Rome, Padua, and Bari, with launches expected before the end of 2025.
Each hub will be equipped with OCS Lung, Heart, and Liver Systems, staffed by clinical perfusionists, and supported by a National Command Center in Santa Giulia, Milan, to provide 24/7 technological, clinical, and logistical support aimed at increasing donor organ utilization across Italy.
TransMedics (Nasdaq: TMDX) announced management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York.
The event is scheduled for Tuesday, December 2, 2025 at 9:30 a.m. ET at the Lotte New York Palace. A live and archived webcast will be available on the company's Investors website and the standard investor presentation is posted at the same link.
TransMedics (Nasdaq: TMDX) on October 27, 2025 granted inducement equity awards to 15 new employees under Nasdaq Listing Rule 5635(c)(4) and the TransMedics Inducement Plan. The company granted non-qualified stock options to purchase an aggregate of 27,582 shares and 18,299 restricted stock units.
Options carry a $132.45 per-share exercise price (closing price on October 27, 2025), a 10-year term, and vest 25% after one year with the remainder vesting monthly over the next three years. RSUs vest 25% on each of the first four anniversaries of employment, each subject to continued service and plan terms.
TransMedics (Nasdaq: TMDX) reported third quarter 2025 results on October 29, 2025, with Q3 revenue of $143.8 million, up 32% year‑over‑year, and net income of $24.3 million or $0.66 per diluted share. Gross margin was 59% and operating expenses were $61.3 million. Cash totaled $466.2 million as of September 30, 2025. The company owns 21 aircraft as of September 30, 2025 and 22 as of October 29, 2025, and announced a strategic collaboration with Mercedes‑Benz to deploy dedicated organ-transport vehicles in Italy. TransMedics raised and narrowed its full‑year 2025 revenue guidance to $595 million–$605 million.
TransMedics (Nasdaq:TMDX) will report third quarter 2025 financial results after market close on Wednesday, October 29, 2025.
The TransMedics management team will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT; domestic dial-in is (844) 676-6010 and international dial-in is (412) 634-6944. A live and archived webcast will be available in the Investors section at https://investors.transmedics.com/.
TransMedics (NASDAQ: TMDX) has announced a strategic collaboration with Mercedes-Benz to establish Italy's first dedicated organ transplantation ground transportation network. The initiative will deploy specially equipped Mercedes-Benz V-Class vehicles across four National OCS Program (NOP) hubs in Milan, Rome, Padua, and Bari.
The network will support TransMedics' Organ Care System (OCS) perfusion technology and will be operational by the end of 2025. Each hub will be equipped with OCS Lung, Heart, and Liver Systems and staffed with clinical perfusionists, providing 24/7 support to transplant centers. The Italian National Command Center will be based in Santa Giulia, Milan.
This collaboration marks TransMedics' first step in replicating its successful U.S. NOP model in Europe, potentially laying the groundwork for a broader European transplant logistics network.
TransMedics (NASDAQ: TMDX), a medical technology company focused on organ transplant therapy, has announced its participation in two upcoming investor conferences in New York this September.
Management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 10:00 a.m. EST, followed by a presentation at the Baird 2025 Global Healthcare Conference on September 9, 2025, at 12:15 p.m. EST. Both presentations will be available via webcast on the company's investor relations website.
TransMedics (Nasdaq: TMDX) has received FDA conditional IDE approval to initiate its Next-Generation OCS ENHANCE Heart trial. The trial consists of two parts: Part A will evaluate prolonged heart perfusion using OCS™ Heart System, while Part B aims to demonstrate superiority of OCS Heart perfusion in donation after brain death (DBD) cases compared to static cold storage methods.
The groundbreaking trial is expected to include over 650 patients, potentially making it the largest heart preservation for transplant trial worldwide. The company plans to initiate both the ENHANCE Heart and DENOVO Lung trials in Q4 2025, with expectations for these trials to drive clinical adoption throughout 2026 and beyond.